摘要
目的评价经尿道膀胱肿瘤电切术(TURBT)联合羟基喜树碱或吡柔比星膀胱内灌注治疗浅表性膀胱癌的疗效。方法 36例浅表性膀胱癌患者行TURB t术,其中22例术后1周开始行吡柔比星膀胱灌注,另外14例行羟基喜树碱膀胱灌注化疗,定期复查B超和膀胱镜,随访3年观察肿瘤的复发率。结果吡柔比星化疗1例失访,其余21例患者术后3年、5年的肿瘤复发率分别为19.05%、28.57%;14例行羟基喜树碱灌注后3年、5年时的肿瘤复发率分别为21.43%、42.85%。结论吡柔比星与羟基喜树碱对浅表性膀胱癌的疗效确切,无明显差异性,均可有效降低膀胱癌的近期复发率。
Objective To evaluate the efficacy of transurethral resection of bladder tumor（TURBT） combined with pirarubicin（THP） or hydroxycamptothecin intravesical administration to prevent recurrence of superficial bladder cancer.Methods 36 patients with superficial bladder cancer undergo TURBT,of which 22 cases with THP intravesical administration after 1 week of,another 14 cases with Hydroxycamptothecin chemotherapy.Follow-up 5-year by periodically gave cystoscopy examination or B-mode ultrasound to evaluation the tumor recurrence rate.Results 1 patient with THP treatment was Loss of follow up,the recurrence rate for 3,5 years are 19.05%,28.57%,in pirarubicin treated group,and 21.43%,42.85% respectively in Hydroxycamptothecin treated group.Conclusion THP and HCPT can prevent relapse of superficial bladder cancer effectively,have no significant difference,can decrease the recurrence rate of superficial bladder cancer.
出处
《中外医学研究》
2011年第15期20-21,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
膀胱癌
吡柔比星
羟基喜树碱
Bbladder cancer
Pirarubicin
Hydroxycamptothecine
